

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for the non-invasive early detection of colon cancer ~~and/or~~ intestinal cancer precursor cells by means of mutational analysis of the genes for APC, K-ras, β -catenin and B-raf in a sample, characterized in that the method comprises the following steps:
 - collecting a stool ~~and/or tissue~~ sample,
 - homogenizing the sample,
 - obtaining DNA from the sample,
 - performing an amplification reaction in the genes for APC, K-ras, β -catenin and B-raf,
using the primers
SEQ ID NO. 1
SEQ ID NO. 2
SEQ ID NO. 3
SEQ ID NO. 4
SEQ ID NO. 5
SEQ ID NO. 6
SEQ ID NO. 7
SEQ ID NO. 8
SEQ ID NO. 9
SEQ ID NO. 10
or alternatively
SEQ ID NO. 15
SEQ ID NO. 16
for APC, the primers
SEQ ID NO. 11
SEQ ID NO. 12
for K-ras, the primers

SEQ ID NO. 13
SEQ ID NO. 14
for β -catenin, and the primers
SEQ ID NO. 17
SEQ ID NO. 18
for B-raf,
wherein amplification products are formed, and
performing a mutational analysis in the amplification products.

2. (Original) The method according to claim 1,
characterized in that
the detection of mutations in selected sections of the genes for APC, K-ras, β -catenin and B-raf is effected by means of a DNA chip, said DNA chip including probes for APC, K-ras, β -catenin and B-raf from those regions of the above-mentioned genes that are flanked by the primer sequences specified in claim 1.
3. (Previously Presented) The method according to claim 1,
characterized in that
the APC, K-ras, β -catenin and B-raf genes are accumulated from total DNA by hybridizing sequence-specific biotinylated oligonucleotides with the genes for APC, K-ras, β -catenin and B-raf using coupling of the biotin residue to streptavidin and subsequent separation via magnetic particles.
4. (Previously Presented) The method according to claim 1,
characterized in that
amplification products, especially PCR products, are separated in an agarose gel for control purposes prior to purification.
5. (Previously Presented) The method according to claim 1,
characterized in that
the mutational analysis of the PCR products is effected using electrophoretic techniques, preferably SSCP, alternatively by means of a chromatographic procedure, preferably an HPLC-based procedure.
6. (Previously Presented) The method according to claim 5,
characterized in that

detected mutagenic conformations of a single strand are isolated and optionally sequenced.

7. (Previously Presented) Primer sequences selected from the group comprising:

the primers

SEQ ID NO. 1

SEQ ID NO. 2

SEQ ID NO. 3

SEQ ID NO. 4

SEQ ID NO. 5

SEQ ID NO. 6

SEQ ID NO. 7

SEQ ID NO. 8

SEQ ID NO. 9

SEQ ID NO. 10

or alternatively

SEQ ID NO. 15

SEQ ID NO. 16

for APC, the primers

SEQ ID NO. 11

SEQ ID NO. 12

for K-ras, the primers

SEQ ID NO. 13

SEQ ID NO. 14

for β -catenin, and the primers

SEQ ID NO. 17

SEQ ID NO. 18

for B-raf.

8. Canceled.

9. (Previously Presented) A kit, comprising primers selected from the group comprising:

the primers

SEQ ID NO. 1

SEQ ID NO. 2

SEQ ID NO. 3
SEQ ID NO. 4
SEQ ID NO. 5
SEQ ID NO. 6
SEQ ID NO. 7
SEQ ID NO. 8
SEQ ID NO. 9
SEQ ID NO. 10
or alternatively
SEQ ID NO. 15
SEQ ID NO. 16
for APC, the primers
SEQ ID NO. 11
SEQ ID NO. 12
for K-ras, the primers
SEQ ID NO. 13
SEQ ID NO. 14
for β -catenin, and the primers
SEQ ID NO. 17
SEQ ID NO. 18
for B-raf,
and optionally information relating to combining the contents of the kit.

10. Canceled.
11. (New) A method for the detection of colon cancer or colon cancer precursor cells using the kit according to claim 9.